Researchers from ADC Therapeutics SA presented the discovery and preclinical evaluation of a novel camptothecin-based Claudin-6-specific antibody-drug conjugate (ADC), GB01-VA-PL2202.
Researchers from Peptidream Inc. presented preclinical characterization of novel carbonic anhydrase IX (CAIX)-targeting radiopeptides, [64Cu]PD-32766 and [177Lu]PD-32766, being developed for the diagnosis and treatment of clear cell renal cell carcinoma (ccRCC), respectively.
Researchers from Egle Therapeutics SAS presented the discovery of a novel immunocytokine, EGL-001, designed to selectively target tumor-infiltrating regulatory T cells (Tregs).
The TEAD family of transcription factors are regulated by the Hippo tumor suppressor pathway and they act by binding the co-activators YAP and TAZ that drive the transcription of genes involved in cell survival, proliferation, migration, differentiation and resistance.
Chong Kun Dang Pharm (CKD Pharm) has presented data on their c-Met-targeting antibody-drug conjugate (ADC) CKD-703 for the treatment of solid tumors. CKD-703 was designed based on site-specific conjugation, with a stable and homogeneous drug-antibody ratio profile.
Researchers from Axcynsis Therapeutics Pte. Ltd. presented the development and preclinical characterization of AT-2604, a novel antibody-drug conjugate (ADC) targeting the placental alkaline phosphatases, ALPP and ALPPL2.
Peptidream Inc. has reported that an early-phase clinical trial for 64Cu-PD-32766, a 64Cu-labeled radiopharmaceutical targeting carbonic anhydrase IX (CAIX), for patients with clear cell renal cell carcinoma has been approved by the clinical review board of the National Cancer Center Hospital East in Japan.
Researchers from Haisco Pharmaceutical Group Co. Ltd. presented the discovery and preclinical characterization of a brain-penetrating BRAF paradox breaker, HSK-42360, being developed for the treatment of BRAF-driven cancers. HSK-42360 proved to be a potent BRAF V600E inhibitor (IC50=5 nM) with selectivity over wild-type BRAF.
The existence of two approved therapies, Lumakras (sotorasib, Amgen Inc.) and Karzati (adagrasib, Mirati Therapeutics Inc.), has been a triumphant success against KRAS, a protein that was once considered undruggable.
RSS
